Hansa Biopharma — Maj 2023
-
Mbcruise..Jeg tror at alle os der har fulgt forløbet med ekspertudvalget fredag ved, at sagen ikke er afgjort endnu. Men da ekspertudtalelser, i forbindelse med eventuel fast track til medicin i tidlig faseforsøg til alvorlige sygdomme uden anden reel god behandlingsmulighed, er eksperterne anbefaling ofte meget delte.
-
8-6 i favør for Sarepta burde i den sammenhæng gøre nogen af de mange shortere nervøse. En positiv afgørelse om 14 dage vil betyde en meget stor stigning i kursen på Hansa Biopharma.
-
-
Nye indlæg i Bents tråd: https://www.proinvestor.com/boards/112647/#112655
-
Kort video: Opdatering: Zealand Pharma' Bavarian' Hansa Biopharma - Fantastisk udvikling i aktiekursen for Zealand Pharma. Det går hedt for sig i Bavarian Nordic-chatten - men hvad er selskabets business case? Hansa Biopharma afventer grønt lys til at køre videre i accelereret proces med stof inden for genterapi - og hvis det lykkes med en eventuel endelig fremtidig godkendelse, ser det for alvor godt ud for selskabet. https://www.proinvestor.com/boards/112684/
-
Bioinvest..."Hansa Biopharma's enzyme cleaving technology imlifidase may potentially be used as a pre-treatment to SRP-9001 in up to 14% of the DMD patient population and if successful in both DMD and LGMD Hansa Biopharma will be eligible to receive up to USD 400 million in milestones from Sarepta Therapeutics plus up to midteens in royalty payments and sales of imlifidase.
-
According to Fierce Biotech, expectations in DMD are high with SRP-9001 potentially be one of the biggest biotech product launches in 2023 with annual sales of more than USD 2 billion in less than five years". https://proinvestor.com/boards/112647/
-
Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001
(05/24/23 8:00 AM EDT)
New regulatory action date is June 22, 2023 ...
-
.... CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 24, 2023-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today provided the following update on the Biologics License Application (BLA) for SRP-9001 (delandistrogene moxeparvovec), which is currently under review for the treatment of ambulant individuals with Duchenne muscular dystrophy (DMD) who have a confirmed mutation of the DMD gene.
spændende med den 29 maj lad os bare forsætte stigningen frem mod da gen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind